{"doc_id": "si-2023-0005-reg-1", "parent_doc_id": "si-2023-0005", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 5 of 2023", "title": "“Principal Regulations” means the Misuse of Drugs (Prescription and Control", "year": 2023, "heading": "1. These Regulations may be cited as the Misuse of Drugs (Prescription", "text_raw": "1. These Regulations may be cited as the Misuse of Drugs (Prescription \nand Control of Supply of Cannabis for Medical Use) (Amendment) \nRegulations 2023. \n\nDefinitions", "text_norm": "1 regulation may cited misuse drug (prescription control supply cannabis medical use) (amendment) regulation 2023 definition", "start_char": 660, "end_char": 830, "source_path": "downloads\\2023\\2023_0005.pdf", "extraction_method": "pdfminer", "checksum": "sha256:66878a88d98e132b1e7ef6a3f50b1463d842f52e274b456e055e7d09697789e2", "cross_refs": []}
{"doc_id": "si-2023-0005-reg-2", "parent_doc_id": "si-2023-0005", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 5 of 2023", "title": "“Principal Regulations” means the Misuse of Drugs (Prescription and Control", "year": 2023, "heading": "In these Regulations-", "text_raw": "2. \n\nIn these Regulations- \n\n“Principal Regulations” means the Misuse of Drugs (Prescription and Control \nof Supply of Cannabis for Medical Use) Regulations 2019 (S.I. No. 262 of \n2019) as amended by the Misuse of Drugs (Prescription and Control of Supply \nof Cannabis for Medical Use) (Amendment) Regulations 2021 (S.I. No. 557 of \n2021) and Misuse of Drugs (Prescription and Control of Supply of Cannabis \nfor Medical Use) (Amendment) Regulations 2022 (S.I. No. 237 of 2022). \n\nAmending the Principal Regulations", "text_norm": "2 regulations- principal regulation mean misuse drug (prescription control supply cannabis medical use) regulation 2019 (s.i no 262 2019) amended misuse drug (prescription control supply cannabis medical use) (amendment) regulation 2021 (s.i no 557 2021) misuse drug (prescription control supply cannabis medical use) (amendment) regulation 2022 (s.i no 237 2022) amending principal regulation", "start_char": 830, "end_char": 1347, "source_path": "downloads\\2023\\2023_0005.pdf", "extraction_method": "pdfminer", "checksum": "sha256:66878a88d98e132b1e7ef6a3f50b1463d842f52e274b456e055e7d09697789e2", "cross_refs": []}
{"doc_id": "si-2023-0005-reg-3", "parent_doc_id": "si-2023-0005", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 5 of 2023", "title": "“Principal Regulations” means the Misuse of Drugs (Prescription and Control", "year": 2023, "heading": "3. The Principal Regulations are amended by substituting for Schedule 1", "text_raw": "3. The Principal Regulations are amended by substituting for Schedule 1 \n\nthe following; \n\n“SCHEDULE 1 \n\nSpecified Controlled Drugs \n\nRegulation 2 \n\nName of Cannabis \nproduct or \npreparation and \nbrand name \n\nDosage \nform \n\nConcentration of THC \n(percentage, weight/weight or \nweight/volume) \n\nName of \nmanufacturer \n\nAurora High \n\nCBD Oil Drops \n\nOral \nsolution \n\nLess than 3% w/v (< 30mg/ml) \n\nThis product also contains \ncannabidiol (CBD) 60% w/v \n(600mg/ml) \n\nCannEpil ™ \n\nOral \nsolution", "text_norm": "3 principal regulation amended substituting schedule 1 following schedule 1 specified controlled drug regulation 2 name cannabis product preparation brand name dosage form concentration thc (percentage weight weight weight volume) name manufacturer aurora high cbd oil drop oral solution le 3 w v ( 30mg ml) product also contains cannabidiol (cbd) 60 w v (600mg ml) cannepil (tm) oral solution", "start_char": 1347, "end_char": 1841, "source_path": "downloads\\2023\\2023_0005.pdf", "extraction_method": "pdfminer", "checksum": "sha256:66878a88d98e132b1e7ef6a3f50b1463d842f52e274b456e055e7d09697789e2", "cross_refs": []}
{"doc_id": "si-2023-0005-reg-0", "parent_doc_id": "si-2023-0005", "section_id": "reg-0", "section_label": "Regulation 0.", "si_number": "S.I. No. 5 of 2023", "title": "“Principal Regulations” means the Misuse of Drugs (Prescription and Control", "year": 2023, "heading": "0.5% w/v (5mg/ml)", "text_raw": "0.5% w/v (5mg/ml) \n\nAurora Cannabis \nEnterprises Inc., \n4439 Township \nRoad 304, \nCremona, Alberta, \nCanada, T0M 0R0 \n\nMGC \nPharmaceuticals \nd.o.o., Kamniška \nulica 29, 1000, \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 24th January, 2023. \n\n \n \n \n \n \n \n \n \n \n\f[5] 3 \n\nThis product also contains \ncannabidiol (CBD) 10% w/v \n(100mg/ml) \n\nLjubljana, \nSlovenia \n\nTilray Oral Solution \nTHC10:CBD10 \n(25ml) \n\nOral \nsolution \n\n1% w/v (10mg/ml) \n\nThis product also contains \ncannabidiol (CBD) 1% w/v \n(10mg/ml) \n\nAurora Sedamen \nSoftgels \n\nCapsules \n\n5mg/capsule \n\nThis product also contains \ncannabidiol (CBD) less than", "text_norm": "0.5 w v (5mg ml) aurora cannabis enterprise inc 4439 township road 304 cremona alberta canada t0m 0r0 mgc pharmaceutical d.o.o kamniska ulica 29 1000 notice making statutory instrument published iris oifigiuil 24th january 2023 5 3 product also contains cannabidiol (cbd) 10 w v (100mg ml) ljubljana slovenia tilray oral solution thc10 cbd10 (25ml) oral solution 1 w v (10mg ml) product also contains cannabidiol (cbd) 1 w v (10mg ml) aurora sedamen softgels capsule 5mg capsule product also contains cannabidiol (cbd) le", "start_char": 1841, "end_char": 2501, "source_path": "downloads\\2023\\2023_0005.pdf", "extraction_method": "pdfminer", "checksum": "sha256:66878a88d98e132b1e7ef6a3f50b1463d842f52e274b456e055e7d09697789e2", "cross_refs": []}
{"doc_id": "si-2023-0005-reg-0", "parent_doc_id": "si-2023-0005", "section_id": "reg-0", "section_label": "Regulation 0.", "si_number": "S.I. No. 5 of 2023", "title": "“Principal Regulations” means the Misuse of Drugs (Prescription and Control", "year": 2023, "heading": "0.2mg/capsule", "text_raw": "0.2mg/capsule \n\nOleo Bedrobinol \n\nDried \nflower", "text_norm": "0.2mg capsule oleo bedrobinol dried flower", "start_char": 2501, "end_char": 2551, "source_path": "downloads\\2023\\2023_0005.pdf", "extraction_method": "pdfminer", "checksum": "sha256:66878a88d98e132b1e7ef6a3f50b1463d842f52e274b456e055e7d09697789e2", "cross_refs": []}
{"doc_id": "si-2023-0005-reg-13", "parent_doc_id": "si-2023-0005", "section_id": "reg-13", "section_label": "Regulation 13.", "si_number": "S.I. No. 5 of 2023", "title": "“Principal Regulations” means the Misuse of Drugs (Prescription and Control", "year": 2023, "heading": "13.5% w/w (135mg/g)", "text_raw": "13.5% w/w (135mg/g) \n\nThis product also contains \ncannabidiol (CBD) less than 1.0% \nw/w (less than 10mg/g) \n\nOleo Bedrocan \n\nDried \nflower \n\n22% w/w (220mg/g) \n\nThis product also contains \ncannabidiol (CBD) less than 1.0% \nw/w (less than 10mg/g) \n\nAlthea \nCBD12:THC10 \n(50ml) \n\nOil \n\n1% w/v THC (10mg/ml) \n\nThis product also contains 1.25% \nw/v (12.5mg/ml) cannabidiol \n(CBD) \n\nOleo Genetics \n10:10 \n\nOil (oral \nsolution) \n\n1% w/v (10mg/ml) \n\nThis product also contains \ncannabidiol (CBD) 1% w/v \n(10mg/ml) \n\nOleo Genetics 25:1 Oil (oral \nsolution)", "text_norm": "13.5 w w (135mg g) product also contains cannabidiol (cbd) le 1.0 w w (less 10mg g) oleo bedrocan dried flower 22 w w (220mg g) product also contains cannabidiol (cbd) le 1.0 w w (less 10mg g) althea cbd12 thc10 (50ml) oil 1 w v thc (10mg ml) product also contains 1.25 w v (12.5mg ml) cannabidiol (cbd) oleo genetics 10 10 oil (oral solution) 1 w v (10mg ml) product also contains cannabidiol (cbd) 1 w v (10mg ml) oleo genetics 25 1 oil (oral solution)", "start_char": 2551, "end_char": 3102, "source_path": "downloads\\2023\\2023_0005.pdf", "extraction_method": "pdfminer", "checksum": "sha256:66878a88d98e132b1e7ef6a3f50b1463d842f52e274b456e055e7d09697789e2", "cross_refs": []}
{"doc_id": "si-2023-0005-reg-2", "parent_doc_id": "si-2023-0005", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 5 of 2023", "title": "“Principal Regulations” means the Misuse of Drugs (Prescription and Control", "year": 2023, "heading": "2.5% w/v (25mg/ml)", "text_raw": "2.5% w/v (25mg/ml) \n\nThis product also contains \ncannabidiol (CBD) <0.1% w/v \n(<1mg/ml) \n\n”. \n\nTilray Portugal \nUnipessoal Lda., \nZona Industrial de \nCantanhede, Lote \n121, Cantanhede, \n3060-197, \nPortugal \n\nAurora Cannabis \nEnterprises Inc. \n4250 14th \nAvenue, \nMarkham, \nOntario, Canada \nL3R 0J3 \n\nBureau voor \nMedicinale \nCannabis Postbus \n16114 2500 BC \nDEN HAAG \nThe Netherlands \n\nBureau voor \nMedicinale \nCannabis Postbus \n16114 2500 BC \nDEN HAAG \nThe Netherlands \n\nTasmanian \nAlkaloids pty Ltd \nT/A Extractas \nBioscience, \nWestbury, \nTasmania, \nAustralia 7303 \n\nADREX Pharma \nGmbH \nFirmungstrabe 4 \n56068 Koblenz \nGermany \n\nADREX Pharma \nGmbH \nFirmungstrabe 4 \n56068 Koblenz \nGermany \n\n \n \n \n \n \n \n \n \n \n\f4 [5] \n\nGIVEN under my Official Seal, \n\n19 January, 2023. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n\f[5] 5", "text_norm": "2.5 w v (25mg ml) product also contains cannabidiol (cbd) 0.1 w v ( 1mg ml)  tilray portugal unipessoal lda zona industrial de cantanhede lote 121 cantanhede 3060-197 portugal aurora cannabis enterprise inc 4250 14th avenue markham ontario canada l3r 0j3 bureau voor medicinale cannabis postbus 16114 2500 bc den haag netherlands bureau voor medicinale cannabis postbus 16114 2500 bc den haag netherlands tasmanian alkaloid pty ltd extractas bioscience westbury tasmania australia 7303 adrex pharma gmbh firmungstrabe 4 56068 koblenz germany adrex pharma gmbh firmungstrabe 4 56068 koblenz germany 4 5 given official seal 19 january 2023 stephen donnelly minister health 5 5", "start_char": 3102, "end_char": 3943, "source_path": "downloads\\2023\\2023_0005.pdf", "extraction_method": "pdfminer", "checksum": "sha256:66878a88d98e132b1e7ef6a3f50b1463d842f52e274b456e055e7d09697789e2", "cross_refs": []}
{"doc_id": "si-2023-0005-explanatory-note", "parent_doc_id": "si-2023-0005", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 5 of 2023", "title": "“Principal Regulations” means the Misuse of Drugs (Prescription and Control", "year": 2023, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThe purpose of these Regulations is to update and replace the current Schedule \n1, in the Misuse of Drugs (Prescription and Control of Supply of Cannabis for \nMedical Use) Regulations 2019 (as amended) (“the Principal Regulations”), in \norder to include additional cannabis products or preparations for medical use as \n“specified controlled drugs”. \n\nThe purpose of the Principal Regulations is to allow additional cannabis \nproducts or preparations for medical use to be prescribed and supplied under \ncertain circumstances for the treatment of persons with certain medical \nconditions under the care of a medical consultant. \n\nThese Regulations may be cited as the Misuse of Drugs (Prescription and \nControl of Supply of Cannabis for Medical Use) (Amendment) Regulations", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) purpose regulation update replace current schedule 1 misuse drug (prescription control supply cannabis medical use) regulation 2019 (as amended) ( principal regulation ) order include additional cannabis product preparation medical use specified controlled drug  purpose principal regulation allow additional cannabis product preparation medical use prescribed supplied certain circumstance treatment person certain medical condition care medical consultant regulation may cited misuse drug (prescription control supply cannabis medical use) (amendment) regulation", "start_char": 3943, "end_char": 4832, "source_path": "downloads\\2023\\2023_0005.pdf", "extraction_method": "pdfminer", "checksum": "sha256:66878a88d98e132b1e7ef6a3f50b1463d842f52e274b456e055e7d09697789e2", "cross_refs": []}
{"doc_id": "si-2023-0005-reg-2023", "parent_doc_id": "si-2023-0005", "section_id": "reg-2023", "section_label": "Regulation 2023.", "si_number": "S.I. No. 5 of 2023", "title": "“Principal Regulations” means the Misuse of Drugs (Prescription and Control", "year": 2023, "heading": "BAILE ÁTHA CLIATH", "text_raw": "2023. \n\n \n \n \n \n \n \n \n \n \n \n\f6 [5] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.00 \n\n(DH-452) 75. 01/23. Propylon.", "text_norm": "2023 6 5 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 3.00 (dh-452) 75 01 23 propylon", "start_char": 4832, "end_char": 5353, "source_path": "downloads\\2023\\2023_0005.pdf", "extraction_method": "pdfminer", "checksum": "sha256:66878a88d98e132b1e7ef6a3f50b1463d842f52e274b456e055e7d09697789e2", "cross_refs": []}
